

Paper No. \_\_\_\_\_  
Filed: June 3, 2016

Filed on behalf of: Mylan Pharmaceuticals Inc.  
By: Steven W. Parmelee  
Michael T. Rosato  
Jad A. Mills  
WILSON SONSINI GOODRICH & ROSATI  
701 Fifth Avenue, Suite 5100  
Seattle, WA 98104-7036

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

MYLAN PHARMACEUTICALS INC.,  
Petitioner,

v.

ALLERGAN, INC.,  
Patent Owner.

---

Case No. IPR2016-01129  
Patent No. 8,642,556

---

**PETITION FOR INTER PARTES REVIEW OF  
U.S. PATENT NO. 8,624,556**

## TABLE OF CONTENTS

	<u>Page</u>
I. INTRODUCTION .....	1
A. Brief Overview of the '556 Patent .....	2
B. Brief Overview of the Prosecution History .....	3
C. Brief Overview of the Scope and Content of the Prior Art .....	6
D. Brief Overview of the Level of Skill in the Art .....	10
II. GROUNDS FOR STANDING .....	11
III. MANDATORY NOTICES UNDER 37 C.F.R. § 42.8 .....	11
IV. STATEMENT OF THE PRECISE RELIEF REQUESTED .....	12
V. STATEMENT OF NON-REDUNDANCY .....	13
VI. CLAIM CONSTRUCTION .....	14
A. “buffer” .....	14
B. “substantially no detectable concentration” .....	14
C. “effective amount,” “therapeutically effective,” “overall efficacy,” and “therapeutic effectiveness” .....	15
D. “adverse events” and “side effects” .....	16
E. “breaks down” .....	16
VII. BACKGROUND KNOWLEDGE IN THE ART PRIOR TO SEPTEMBER 15, 2003 .....	17
VIII. DETAILED EXPLANATION OF GROUNDS FOR UNPATENTABILITY .....	22
A. [Ground 1] Claims 1-20 are Anticipated under 35 U.S.C. § 102(b) by Ding '979 .....	22
i. Claims 1-10 and 12-13 .....	22
ii. Claim 14 .....	29

iii.	Claims 15-17 .....	29
iv.	Claims 11 and 18-20 .....	30
B.	[Ground 2] Claims 1-20 are Obvious under 35 U.S.C. § 103 over Ding '979 and Sall .....	34
i.	Claims 1-10, 12-13.....	34
ii.	Claim 14.....	36
iii.	Claims 15-17 .....	37
iv.	Claims 11 and 18-20 .....	38
C.	[Ground 3] Claims 14 and 19 are Obvious under 35 U.S.C. § 103 over Ding '979, Sall, and Glonek.....	41
D.	[Ground 4] Claims 11, 18, and 20 are Obvious under 35 U.S.C. § 103 over Ding '979, Sall, and Acheampong .....	43
E.	[Ground 5] Claim 19 is Obvious under 35 U.S.C. § 103 over Ding '979, Sall, Glonek, and Acheampong .....	45
IX.	NO OBJECTIVE INDICIA OF NON-OBVIOUSNESS .....	45
A.	No Unexpected Results .....	46
B.	No Evidence of Commercial Success .....	56
C.	No Industry Praise.....	57
D.	No Long-Felt, Unmet Need.....	58
E.	No Failure of Others.....	58
X.	CONCLUSION.....	59
XI.	CERTIFICATE OF COMPLIANCE .....	60
XII.	PAYMENT OF FEES UNDER 37 C.F.R. §§ 42.15(A) AND 42.103 .....	61
XIII.	APPENDIX – LIST OF EXHIBITS .....	62

## I. INTRODUCTION

Mylan Pharmaceuticals Inc. (“Petitioner”) requests review of U.S. Patent No. 8,642,556 to Acheampong *et al.* (“the ’556 patent,” EX1001) that issued on February 4, 2014. PTO records indicate the ’556 patent is assigned to Allergan, Inc. (“Patent Owner”). This Petition demonstrates that there is a reasonable likelihood that claims 1-20 of the ’556 patent are unpatentable for failure to distinguish over the asserted prior art. Additional petitions are being filed to address related patents that are assigned to Patent Owner. All challenged patents are continuations from the same family and are terminally disclaimed over one another. The patents claim an ophthalmic emulsion for the treatment of overlapping ocular disorders, or conventional methods of administering the emulsion.

The ’556 patent claims a topical ophthalmic emulsion as in related U.S. Patent No. 8,685,930, but further recites a comparative clause, where an effect of the emulsion is compared to a prior art emulsion. Yet each element of the claimed emulsion, including the claimed cyclosporin A (“CsA”) and castor oil percentages and other standard emulsion ingredients, was disclosed in a single prior art reference (Ding ’979) for the same therapeutic uses, *i.e.*, treating dry eye disease. During prosecution of a parent application, applicants even admitted that the claimed emulsion containing 0.05% CsA and 1.25% castor oil “is squarely within the teaching of the Ding [’979] reference” and “would have been obvious” to a person of skill in the art at the time of the invention. EX1005, 0435; EX1002, ¶18.

Four years later, in prosecuting the '556 patent as a continuation application, applicants changed course and attempted to withdraw these admissions. EX1004, 0007. They argued that data collected *after* their earlier admissions established patentability because of an alleged unexpected result that the emulsion was “equally or more therapeutically effective for the treatment of dry eye/keratoconjunctivitis sicca than the formulation containing 0.10% by weight cyclosporin A and 1.25% by weight castor oil.” EX1004, 0007, 0205; EX1002, ¶¶20-22. But the supposed “unexpected results” are weak, at best, and fail to rebut the strong evidence of obviousness. The data relied upon by applicants lack scientific parameters necessary to demonstrate statistical significance and materiality and, in many cases, appear to be copies of previously published graphs from a 102(b) prior art reference, Sall. Thus, Patent Owner’s cited evidence does not support non-obviousness of the claims, and merely confirms that the results were already disclosed in the prior art.

#### **A. Brief Overview of the '556 Patent**

The '556 patent has an earliest claimed priority date of September 15, 2003. Independent claim 1 recites an emulsion of 0.05% CsA, 1.25% castor oil, polysorbate 80, acrylate/C10-30 alkyl acrylate cross-polymer (“cross-polymer”) and water that is therapeutically effective in treating dry eye disease and “provides overall efficacy substantially equal to a second topical ophthalmic emulsion comprising cyclosporin A in an amount of about 0.1% by weight and castor oil in an amount of about 1.25% by weight.” Claims 2-6 and 9-10 recite that the emulsion comprises a tonicity or demulcent agent, specifically glycerine, and/or a

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.